9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Exclusion Criteria

• •Anti-tumor treatment such as chemotherapy and radiotherapy within 21 days prior to the first dose of study drug.
• •Major surgery within 28 days prior to first dose of study drug.
• •PD-1/PD-L1/PD-L2 inhibitors used in the previous treatment for La/m UC.
• •Previous treatment with ADCs conjugated with MMAE payload.
• •Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
• •Peripheral neuropathy Grade ≥ 2.
• •Poorly controlled blood sugar.
• •Increased risks of corneal disease assessed by the investigator prior to the first dose of study drug.
• •Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.
• •Active infections, such as uncontrolled HBV/HCV/HIV/TB infection, etc.
• •Other serious or uncontrolled diseases, such as serious interstitial pneumonia/asthma, serious thromboembolic events, etc.
• •Poorly controlled central nervous system metastases.
• •Organ transplantation or allogeneic hematopoietic stem cell transplantation in the past.
• •History of drug abuse or mental illness.
• •Known allergic sensitivity to any of the ingredients of the study drug.
• •Any P-glycoprotein (P-gp) inducers/inhibitors or potent CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug.
• •History of autoimmune disease requiring systemic treatment within 2 years before the first dose.
• •Any live vaccines within 4 weeks before first dose of study drug or during the study.
• •Use of any investigational drug or medical instruments within 28 days prior to the first dose of study drug.
• •History of another malignancy within 3 years before the first dose of study drug. Subjects with curable malignancies are allowed.
• •Other conditions unsuitable into the study.